Tegoprubart for ALS
Tegoprubart, from Eledon Therapeutics, is an investigational therapy to slow ALS onset and progression that's now in clinical trials.
Search results for:
A childhood curveball at Halloween guides me in living with ALS
Being told I had ALS felt as if a rug had suddenly been pulled out from under me. My world changed all at once, with no possibility of turning it back. That happened in 2010, and it was certainly a major curveball in my life. But I’ve been living…
Pregnancy can speed ALS severity and progression, review study finds
Pregnancy can worsen the progression of amyotrophic lateral sclerosis (ALS), regardless of whether symptom onset occurs before or during pregnancy, according to a review study. Still, most of the cases reviewed showed that ALS did not affect a woman’s ability to give birth, naturally or by cesarean section, or…
Survey offers look at life, treatment priorities of those living with ALS
People with amyotrophic lateral sclerosis (ALS) report significant changes in lifestyle after their diagnosis, but still have an acceptable quality of life and low stress levels, according to a survey conducted across nine European countries. When asked about new drug development, participants most commonly prioritized treatments that slow…
Man with ALS controls devices using brain-computer interface
A man with amyotrophic lateral sclerosis (ALS) was able to control external devices — lighting and a TV — with only his thoughts using a brain-computer interface (BCI) device, according to a recent study. Called Cortical Communication (CortiCom), the BCI system learns to predict a person’s intended action by…
ALS speech problems
How ALS leads to speech problems | Examples of speech problems | ALS speech therapy | Strategies to help Speech problems are among some of the most common symptoms of amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes the deterioration of motor neurons, the nerve…
BrainStorm making cuts to support new trial, advance NurOwn for ALS
BrainStorm Cell Therapeutics is making strategic adjustments — including cuts in its workforce — to accelerate the clinical development of NurOwn as an amyotrophic lateral sclerosis (ALS) treatment. The decision follows the recent withdrawal of its regulatory application with the U.S. Food and Drug Administration…
Lessons learned from the dysphagia symptoms that come with my ALS
Swallowing. It’s such a simple thing for most to do. But swallowing can also be a scary maneuver, especially when it turns into an ALS symptom called dysphagia. I began experiencing it about four years after my initial ALS diagnosis. And because that was nine years ago,…
FDA names CB03, aiming to protect neurons, an orphan drug for ALS
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to CB03, Zhimeng Biopharma’s small molecule treatment candidate for amyotrophic lateral sclerosis (ALS). CB03 is designed to bolster nerve cell health by regulating potassium channels on these cells, reducing the hyperexcitability that is damaging to…
TUDCA at higher daily dose seen to extend survival: ALS registry study
People with amyotrophic lateral sclerosis (ALS) who are treated daily with 1,000 mg or higher doses of tauroursodeoxycholic acid (TUDCA) tend to live longer than those given standard care alone, according to an analysis of registry data. “In our ‘real-world’ study, patients who received TUDCA at the higher…